ABSTRACT This study evaluated the effect of inhaled volume and simulated inspiratory flow rate ramps on fine particle output from dry powder inhalers (DPIs). A simple, robust system was developed to account for "rate of rise" (ramp) effects while maintaining a constant air flow through a multi-stage liquid impinger (MSLI), used for sizing the emitted particles. Ramps were programmed to reach 30 and 60 L/min over 100 milliseconds; 500 milliseconds; and 1, 2, and 3 seconds. Rotahaler was chosen as the test DPI. Testing was done with simulated inhalation volumes of 2 L and 4 L. Testing was also carried out using the USP apparatus 4. At 30 L/min, for a 2 L volume, the amount of drug exiting the device in fine particle fraction (FPF) increased from 2.33 μg to 6.04 μg from the 3-second ramp to the 100-millisecond ramp, with 11.64 μg in FPF for the USP (no ramp) method. At the same flow rate, for a 4 L volume, FPF increased from 2.23 μg to 8.45 μg, with 10.25 μg for the USP method. At 60 L/min, similar trends were observed. In general, at both flow rates, an increase in FPF was noted going from the shallowest to the steepest ramp. However, there were no significant differences in FPF when a 2 L inhaled volume was compared with a 4 L volume at each flow rate. Overall, these data suggest that the existing USP apparatus may overestimate FPF at flow rates lower than those recommended by the USP.
INTRODUCTION
Passive dry powder inhalers (DPIs) are an established technology for delivery of drugs as aerosols to the lung 1, 2, 3 , and typically consist of a drug admixed with a carrier such as lactose 4 . A primary advantage of DPIs is that they are inherently breath actuated-only releasing drug when the patient inhales. Paradoxically, the major disadvantage of passive DPIs is that the energy derived from the patient's inspiration is utilized as the sole energy source for aerosol generation 5 . Therefore, the entrainment and dispersion performance, and hence the dose delivered by DPIs to the lung, is affected by the patient's ability to inhale appropriately 6, 7 .
The United States Pharmacopeia (USP) includes guidelines for measuring the emitted dose and aerodynamic particle size of some drugs delivered from DPI platforms 8 . The USP method involves testing DPIs at a constant inhaled volume (4 L) and a constant pressure drop (4 Kpa), resulting in a specific test flow rate for each inhaler 9, 10 . We previously described a modification of the emitted dose test, which took into account the different rates at which patients approach their peak inhaled flow rate 11 . This paper expands the utility of this system to permit aerodynamic size distribution measurements with any impactor described in the USP. We studied Apparatus 4, the multi-stage liquid impinger (MSLI) as an example. The MSLI separates dry aerosol particles in a moving air stream on the basis of their aerodynamic diameters 8 and allows an estimate of the fine particle dose or fine particle fraction (FPF) of the aerosol emitted from a DPI. In this article and in many texts, fine particle fraction refers to the fraction of the inhaler output that has an aerodynamic diameter less than about 6 mm 12, 13 . This is often assumed to correlate with the fraction of the drug dose that penetrates the lung during inhalation.
A schematic representation of the USP apparatus for determination of fine particles is shown in Figure 1 . The USP test is assumed to instantaneously generate a preselected peak flow rate and a constant inhaled volume. In reality, when the solenoid valve within the system opens, there is probably some expansion of air in the impinger in response to the sudden pressure drop. However, over a short period of time (in the order of seconds), the flow rate through the DPI and impinger will reach steady state conditions 14 . It is likely that powder emptied prior to attainment of steady state will be inappropriately sized. Current in vitro testing replicates the peak rate at which a patient might be expected to inhale through a DPI, and the volume of their inhalation. However, it does not take into account how this peak flow rate is achieved and does not use the impinger under steady state air flow conditions. This study begins an exploration of the possibility that these observations account for differences that are frequently noticed between in vitro test results and actual in vivo deposition 15, 16 . Our specific aim was to develop and validate a DPI sizing apparatus that could more closely represent in vivo conditions using readily available hardware to modify the USP apparatus. We concede that the flow profiles we used during our tests are not physiologically accurate, but they do represent the extremes of flow rate acceleration that might be AAPS PharmSci 2002; 4 (2) article 6 (http://www.aapspharmsci.org). anticipated in a diverse patient population asked to inhale through a DPI. been described previously 13 . These were combined with the apparatus shown in Figure 3 (Pride Machining Co, Baltimore, MD) to permit emitted dose and aerodynamic particle size distributions to be measured from DPI devices. Simulated inhalations were drawn through the DPI while maintaining a higher but "functionally constant" air flow through the MSLI by the addition of a complementary air stream introduced downstream of the DPI via a manual valve (SS-4P4T2, Nupro Company, Willoughby, Ohio) open to the atmosphere. The outlet of this valve was tapped into the side of an aluminum cylinder designed to accept an epoxy-based adapter (Nephele Enterprise, St Paul, MN) moulded to the shape of the DPI mouthpiece at one end. This cylinder was slid into a larger diameter Plexiglas® cylinder using an O-ring seal. The DPI unit, supported by a holder, was placed inside the aluminum cylinder such that it achieved a tight fit into the mouthpiece adapter. The 2 cylinders together provided an airtight seal around the DPI unit, while a wire mesh in the back of the Plexiglas cylinder held the DPI in place without blocking any air vents at the back of the DPI. 
MATERIALS AND METHOD
Rotahaler® (Glaxo Wellcome Inc, Research Triangle Park, NC) and Ventolin Rotacaps® (albuterol powder for inhalation) were evaluated. Test flow rates of 30 and 60 L/min through the DPI were tested with ramp periods (time required to reach the peak flow rate) of 0 (USP method), 100, and 500 milliseconds, plus 1, 2, and 3 seconds ( Figure 2 ).
The initial weight of each DPI unit was recorded. The USP procedure for fine particle dose determination from the mouthpiece of a DPI was followed as written (instantaneously generated peak flow), and when using flow rate ramps (the apparatus is described later). The DPI unit was reweighed after the run, and the difference in weight calculated (n = 3). The MSLI (USP Apparatus 4, Copley Instruments, Nottingham, England), along with its corresponding induction port, was used for sizing the aerosol. High-performance liquid chromatography (HPLC) analysis was used for quantification of albuterol at each location to determine fine particle output. To test the effect of inhaled volume on fine particle generation, testing was carried out with 2 and 4 L inhaled volumes.
To assess confounding weight changes due to moisture uptake or release, 5 reference experiments were carried out in which loaded DPIs were reweighed without dispensing a dose. Humidity and temperature were measured on the day of each experiment. The temperature was 26 ± 3° C and the relative humidity was 48% ± 8%. A control system and valves capable of ramping up to a predetermined peak air flow rate through a DPI have AAPS PharmSci 2002; 4 (2) article 6 (http://www.aapspharmsci.org). The back of the Plexiglas cylinder was connected to the electronically controlled valve system described previously. The air flow rate through the DPI was measured by connecting a mass flow meter (Model 822S-M-3-0V1, Sierra Instruments, Inc, Monterey, CA) in series with the valve. The front of the aluminum cylinder was connected to the induction port of the MSLI just beyond the point of entry of the compensatory air via an O-ring seal. Air was pulled through the MSLI with 3 vacuum pumps (Model 0323, Gast Manufacturing Corporation, Benton Harbor, MI) connected via a manifold. Another mass flow meter was placed between the vacuum pumps and the MSLI in order to monitor the air flow rate through the MSLI.
Modification of the USP in vitro testing apparatus
To perform each experiment, 20 mL of citratebuffer:methanol (60:40) solvent were introduced into the 4 stages of the MSLI. A glass fiber filter (61664, Gelman Sciences, Ann Arbor, MI) was placed on the filter stage and the induction port was attached. The initial weight of the test DPI was recorded. The DPI was then placed in its holder inside the aluminum cylinder. The Plexiglas cylinder was slid into place, the vacuum pumps were switched on, and the target flow rate was drawn through the MSLI (all air entered via the complimentary air stream valve at this point). The control system then sent a signal corresponding to a particular ramp to open the electronic proportioning valve (air now entered the MSLI through the DPI and complimentary air-stream valve). The increasing air flow through the DPI and total airflow through the MSLI were monitored in real time. When the ramp sequence was complete, the vacuum pump was switched off. The entire assembly was then dismantled and the DPI unit was reweighed. Albuterol in the DPI, induction port, and all impinger locations was quantitatively recovered and analyzed by HPLC.
RESULTS AND DISCUSSION
Air flow through the MSLI was always maintained higher than the flow rate through the DPI. For example, for a 0-30 L/min ramp through the DPI, the flow rate through the MSLI was maintained close to 75 L/min. This was done so that opening the computer-controlled proportioning valve would not cause large flow-rate fluctuations through the MSLI. The flow rate downstream of the MSLI remained within ± 2 L/min of the target flow rate for a 0-30 L/min ramp through the DPI, and within ± 4 L/min for a 0-60 L/min ramp (when the MSLI flow rate was 125 L/min). The cut-off diameter of Stage 2 (used to define the FPF) changes from 6.16 to 6.00 μm when the MSLI flow rate changes from 73 to 77 L/min, and from 4.79 to 4.64 μm when the flow rate changes from 121 to 129 L/min. The changes in cut-off diameters were calculated as a function of flow rate. In each case, the difference in FPF induced by assuming maximum error in the size cutoff was not significantly different when tested by analysis of variance at a significance level of P < .05, followed by a Tukey's Honestly Significant Difference test to determine significant differences between individual group means. (See Table I While the nominal dose of albuterol is 200 μg/Rotacap, results demonstrated that at 30 L/min, for a 2 L inhaled volume, the amount of drug that exited the Rotahaler in the FPF Footnote 1 was only 2.33 μg with the 3-second ramp and rose to only 6.04 μg with the 100-millisecond ramp. Figure 4 shows that 11.64 μg emptied with the USP (no ramp) method. At the same flow rate, for a 4 L volume, this amount increased from 2.23 μg to 8.45 μg as the ramp became steeper and increased to 10.25 μg for the USP method. The total amount of drug recovered Footnote 2 (190.5 μg at 4 L and 204.9 μg at 2 L) was within 5% of the nominal dose. Drug exiting the Rotahaler Footnote 3 for both the inhaled volumes over the full range of ramps studied is summarized in Table 2 and 3. In both tables, the trends obtained were similar, with a greater amount of drug exiting the device with a steeper ramp. The USP apparatus determination was higher than the steepest ramp at this flow rate for both the inhaled volumes. At 60 L/min, for a 2 L inhaled volume, the amount of drug that exited the device in the FPF increased from 7.81 μg to 16.44 μg from the shallowest to the steepest ramp as shown in Figure 5 . The USP apparatus determination under the same conditions showed 20.21 μg in the FPF exiting the device. At the same flow rate, for a 4 L volume the amount of drug exiting the device in the FPF increased from 9.73 μg to 18.94 μg with 21.33 μg present as fine particles using the USP method. For both inhaled volumes at this flow rate the total amount of drug exiting the device also increased from the shallowest to the steepest ramp. Table 4 and 5 summarize the particle sizing data in terms of amounts for both inhaled volumes at 60 L/min. A previous study found that gravimetric emptying tests (which could not differentiate lactose carrier from albuterol) indicated complete powder emptying, even with the shallowest ramp, at flow rates of 90 and 120 L/min through the DPI 13 . This caused us to concentrate on lower flows in this investigation. A more practical limitation was the need for additional vacuum pump capacity to obtain sufficient flow through the MSLI to maintain 90 and 120 L/min through the DPI, with reasonable consistency. This would also require operation of the MSLI outside its calibrated range.
The effect of ramped airflow on powder emptying was greater than its influence on fine particle output from the DPI. A steeper ramp may impart more energy in a shorter time than a shallower ramp. The increased energy could causea powder agglomerate within the DPI to become entrained in the patient's airstream more violently, resulting in significant differences in emptying results. However, with respect to fine-particle generation, the forces between drug particles or drug and carrier particles appear much stronger, and a steep ramp may not necessarily provide enough energy to overcome these attractive forces 17 .
In order to test the effect of inhaled volume on fineparticle generation from a DPI system, data obtained from a 2 L volume was compared with a 4 L volume at each flow rate and for a particular flow rate ramp. For example, at 30 L/min, for a 100-millisecond ramp, the amount of drug exiting the device in FPF was 6.04 μg for a 2 L simulated inhaled volume as compared with 8.45 μg for a 4 L volume. At 60 L/min, for the same ramp, the amount of drug exiting the device in FPF was 16.44 μg for a 2 L volume compared with 18.94 μg for a 4 L inhaled volume. In general, at both flow rates, a higher amount of drug exited the device in the FPF following the larger simulated inhaled volume. However, these differences were not statistically significant (P > .05) in most cases.
Collectively, these results indicated that, at low flow rates (30 and 60 L/min), a small but significant increase in FPF was noted going from the shallowest to the steepest ramp. This may be because a steeper ramp exerts a greater air-impact, causing more particle deaggregation compared with a shallower ramp, thus enhancing the observed fine particle fraction. Also with a shallower ramp, powder within the device may slowly travel a short distance and be caught within crevices or regions of low flow in the device, making aggregated powder less susceptible to break up into finer particles and diminishing their tendency to exit the device even when the flow rate later becomes faster. In short, the rate at which energy is applied to particles, and not just the total amount of energy, influences deaggregation.
At each flow rate and inhaled volume, the USP method produced a higher FPF than even the steepest ramp. For a particular simulated inspiratory flow rate ramp and peak flow rate, there was no significant difference in terms of percent of total drug in FPF when a 2 L volume was compared with a 4 L volume. Although, it was expected that a higher FPF may be obtained with a larger inhaled volume (because of greater energy input), no difference was noted in this study. This may be attributed to variability in our data and a small sample size, but we believe this can be attributed to particles being carried to their final position inside the MSLI early in the simulated inhalation. Therefore, energy imparted to the powder to overcome attractive forces between particles, or particles and substrate, by a 2 L volume may not be significantly different from that provided by a 4 L volume.
CONCLUSION
An in vitro air flow control system, compatible with current compendial testing equipment, has been developed to permit a time-varying air-flow rate profile (a ramp) to be generated through a DPI delivery device while maintaining near-constant flow through an inertial particle-sizing instrument. Using this apparatus, it was found that the FPF determined by the USP apparatus was statistically higher than that achieved with ramps approaching 30 and 60 L/min. These data suggest that the existing USP method may overestimate FPF at flow rates lower than those recommended by the USP (based on device resistance). This in vitro effect may also be present in vivo; however, additional studies will be needed to demonstrate this effect in vivo.
FOOTNOTES
1. Amount of drug exiting device in fine particle fraction is the amount of drug that exits the device and is collected on stages 3, 4, and the filter of the MSLI.
2. Total amount of drug recovered is the total amount of drug collected from the device, induction port, and all the stages of the MSLI.
3. Amount of drug exiting the device refers to the amount of drug that is collected from the induction port and all the stages of the MSLI.
